Suppr超能文献

使用MitraClip进行经皮二尖瓣修复术。

Percutaneous mitral repair with the MitraClip.

作者信息

Maisano F, Alfieri O, La Canna G

机构信息

Cardiochirurgia, Ospedale San Raffaele, Via Olgettina 60, 20132 Milano, Italia.

出版信息

Ann Fr Anesth Reanim. 2011 May;30 Suppl 1:S33-7. doi: 10.1016/S0750-7658(11)70008-9.

Abstract

Mitral regurgitation (MR) is associated with poor prognosis and high incidence of clinical events if left untreated. To reduce the invasiveness of the surgical approach, different types of trans-catheter procedures are becoming available. The MitraClip procedure (Abbott Vascular Inc. Menlo Park, CA) is yet the only available at the moment. The procedure is used to treat high risk surgical candidates with either functional or degenerative MR. Recent trials have shown that the procedure is safer than surgery, although less effective. Efficacy of the procedure depends on several factors, including patient selection, anatomy of the valve and the experience of the operators. However, when treating high risk patients a suboptimal repair obtained with low risk can be a acceptable outcome. In the future, novel devices, improved knowledge, more efficient imaging and transcatheter mitral prosthetic valve implantation may expand the indications to those patients currently not treated by MitraClip for anatomical unsuitability, as well as may improve the results both in term of early efficacy and long term durability.

摘要

二尖瓣反流(MR)若不治疗,与不良预后及高临床事件发生率相关。为降低手术方法的侵入性,不同类型的经导管手术正逐渐可用。MitraClip手术(雅培血管公司,加利福尼亚州门洛帕克)是目前唯一可用的。该手术用于治疗有功能或退行性MR的高风险手术候选者。近期试验表明,该手术比手术更安全,尽管效果较差。该手术的疗效取决于几个因素,包括患者选择、瓣膜解剖结构及操作者经验。然而,在治疗高风险患者时,以低风险获得的次优修复可能是可接受的结果。未来,新型装置、知识的改进、更有效的成像及经导管二尖瓣人工瓣膜植入可能会将适应症扩大到目前因解剖不适合而未接受MitraClip治疗的患者,同时也可能在早期疗效和长期耐久性方面改善结果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验